It’s no secret that Moderna’s R&D efforts have expanded well beyond the realm of COVID-19. CFO Jamey Mock tells us that today the company has more than 40 drugs in its pipeline, with targets such as respiratory, latent, onocology and rare diseases. As he explains, this diversity means that the biotech innovator is reliant not … Continue reading 963: How a Biotech Disrupter Is De-risking R&D | Jamey Mock, CFO, Moderna